TY - JOUR
T1 - PET/MRI for Gastrointestinal Imaging
T2 - Current Clinical Status and Future Prospects
AU - Fraum, Tyler J.
AU - Ludwig, Daniel R.
AU - Hope, Thomas A.
AU - Fowler, Kathryn J.
PY - 2018/9
Y1 - 2018/9
N2 - Positron emission tomography (PET)/computed tomography (CT) with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) has become the standard of care for the initial staging and subsequent treatment response assessment for numerous gastrointestinal malignancies. However, it is often supplemented by magnetic resonance imaging (MRI) for local tumor staging. Hybrid PET/MRI scanners, which acquire PET data and MRI data simultaneously, have the potential to provide accurate whole-body staging in a single examination. Furthermore, to address certain limitations of FDG, many new PET tracers have been developed to probe distinctive aspects of tumor biology.
AB - Positron emission tomography (PET)/computed tomography (CT) with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) has become the standard of care for the initial staging and subsequent treatment response assessment for numerous gastrointestinal malignancies. However, it is often supplemented by magnetic resonance imaging (MRI) for local tumor staging. Hybrid PET/MRI scanners, which acquire PET data and MRI data simultaneously, have the potential to provide accurate whole-body staging in a single examination. Furthermore, to address certain limitations of FDG, many new PET tracers have been developed to probe distinctive aspects of tumor biology.
KW - Colorectal cancer
KW - Hepatocellular carcinoma
KW - Neuroendocrine tumor
KW - PET/MRI
KW - Pancreatic cancer
UR - http://www.scopus.com/inward/record.url?scp=85049452647&partnerID=8YFLogxK
U2 - 10.1016/j.gtc.2018.04.011
DO - 10.1016/j.gtc.2018.04.011
M3 - Review article
C2 - 30115444
AN - SCOPUS:85049452647
VL - 47
SP - 691
EP - 714
JO - Gastroenterology Clinics of North America
JF - Gastroenterology Clinics of North America
SN - 0889-8553
IS - 3
ER -